A stockholder’s recently unsealed complaint lays out the “disturbing details” surrounding the collapse of blood diagnostics company Theranos Inc., accusing its chief executive and former president of committing securities fraud and intentionally misleading investors into funding a now-abandoned business model.
Filed Oct. 10 in the Delaware Court of Chancery, the 66-page document was unsealed days later. In it, San Francisco-based Partner Fund Management accuses Theranos of making “misrepresentations, misleading statements, and material omissions about, among other things, the company’s technology, methods, regulatory interactions, and business plan.”
